BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

Persistent latent reservoir in resting CD4+ T cells is a major obstacle in curing HIV-1 infection. Effective strategies for eradication of the HIV-1 reservoir are urgently needed. We report here for the first time that two BET inhibitors, RVX-208, which has entered phase II clinical trials for diver...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Panpan, Shen, Yinzhong, Yang, He, Wang, Yanan, Jiang, Zhengtao, Yang, Xinyi, Zhong, Yangcheng, Pan, Hanyu, Xu, Jianqing, Lu, Hongzhou, Zhu, Huanzhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709369/
https://www.ncbi.nlm.nih.gov/pubmed/29192216
http://dx.doi.org/10.1038/s41598-017-16816-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709369/
https://www.ncbi.nlm.nih.gov/pubmed/29192216
http://dx.doi.org/10.1038/s41598-017-16816-1

Ejemplares similares